LE ROLE DE LA RIFAMPICINE DANS LA PHASE ULTIME DU TRAITEMENT DE LA TUBERCULOSE MURINE EXPERIMENTALE

Translated title of the contribution: The role of rifampicin in the final stage of treatment of experimental tuberculosis in the mouse

J. Grosset, F. Grumbach, N. Rist

Research output: Contribution to journalArticlepeer-review

Abstract

In the final step of treatment of experimental tuberculosis in the mouse, the role of isoniazid and rifampicin in association is compared with that of isoniazid alone. After 6 months of continuous treatment with isoniazid (25 mg/kg) and rifampicin (25 mg/kg) combined, the mice were divided into 2 groups. In the first group, the mice were treated with isoniazid alone; in the second, with isoniazid plus rifampicin. The complementary treatment lasted either one, two, or three months. Following a six-month observation period without treatment, the percentages of relapses were respectively 75, 25, and 20% in the mice that received 1, 2, or 3 months of complementary treatment with isoniazid alone. The corresponding percentages of 54, 18 and 0% were observed in the mice that received treatment of the same duration with isoniazid and rifampicin combined. The special effectiveness of rifampicin in combating experimental tuberculosis in the mouse is discussed.

Translated title of the contributionThe role of rifampicin in the final stage of treatment of experimental tuberculosis in the mouse
Original languageFrench
Pages (from-to)515-520
Number of pages6
JournalRevue Francaise des Maladies Respiratoires
Volume6
Issue number5
StatePublished - Jan 1 1978

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'The role of rifampicin in the final stage of treatment of experimental tuberculosis in the mouse'. Together they form a unique fingerprint.

Cite this